

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	3,116,282	12/31/63	Hunter	
	A02	3,480,613	11/25/69	Walton	
	A03	3,891,623	06/24/75	Vorbruggen, et al.	
	A04	4,022,889	05/01/77	Bannister et al.	
	A05	4,058,602	11/01/77	Beisler et al.	
	A06	4,209,613	06/24/80	Vorbruggen, et al.	
	A07	4,239,753	12/01/80	Skulnick et al.	
	A08	4,294,766	10/13/81	Schmidt, et al.	
	A09	4,605,659	08/12/86	Verheyden, et al.	
	A10	4,689,404	08/25/87	Kawada, et al.	
	A11	4,754,026	06/28/88	Kawada, et al.	
	A12	4,814,477	03/21/89	Wijnberg, et al.	
	A13	4,880,784	11/14/89	Robins, et al.	
	A14	4,952,740	08/28/90	Juge, et al.	
	A15	5,034,394	07/23/91	Daluge	
	A16	5,122,517	06/16/92	Vince, et al.	
	A17	5,200,514	04/06/93	Chu	
	A18	5,246,924	09/01/93	Fox, et al.	
	A19	5,256,797	10/26/93	Chou, et al.	
	A20	5,322,955	06/21/94	Matsumoto, et al.	
	A21	5,371,210	12/06/94	Chou, et al.	
	A22	5,391,769	02/21/95	Matsumoto, et al.	
	A23	5,401,861	03/28/95	Chou, et al.	
	A24	5,463,092	10/31/95	Hostetler, et al.	
	A25	5,539,116	07/23/96	Liotta, et al.	
	A26	5,565,438	10/15/96	Chu, et al.	
	A27	5,567,688	10/22/96	Chu, et al.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A28	5,587,362	12/24/96	Chu, et al.	
	A29	5,606,048	02/25/97	Chou, et al.	
	A30	5,696,277	12/09/97	Hostetler, et al.	
	A31	5,744,600	04/28/98	Mansuri, et al.	
	A32	5,750,676	05/12/98	Vorbruggen, et al.	
	A33	5,763,418	06/09/98	Matsuda, et al.	
	A34	5,780,617	07/14/98	Van den Bosch, et al.	
	A35	5,789,608	08/04/98	Glazier	
	A36	5,821,357	10/13/98	Chou, et al.	
	A37	5,977,325	11/02/99	McCarthy, et al.	
	A38	6,002,029	12/14/99	Hostetler, et al.	
	A39	6,063,628	05/16/00	Loeb, et al.	
	A40	6,140,310	10/31/00	Glazier	
	A41	6,153,594	11/28/00	Borretzen, et al.	
	A42	6,156,501	12/05/00	McGall, et al.	
	A43	6,172,046	01/09/01	Albrecht	
	A44	6,248,878	06/19/01	Matulic-Adamic, et al.	
	A45	6,252,060	06/26/01	Hostetler	
	A46	6,271,212	08/07/01	Chu, et al.	
	A47	6,277,830	08/21/01	Ganguly, et al.	
	A48	6,348,587	02/19/02	Schinazi, et al.	
	A49	6,369,040	04/09/02	Acevedo, et al.	
	A50	6,436,437	08/20/02	Yatvin, et al.	
	A51	6,448,392	09/10/02	Hostetler, et al.	
	A52	6,455,508	09/24/02	Ramasamy, et al.	
	A53	6,458,772	10/01/02	Zhou, et al.	
	A54	6,458,773	10/01/02	Gosselin, et al.	

LAL-3017173v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A55	6,472,373	10/29/02	Albrecht	
	A56	6,495,677	12/17/02	Ramasamy, et al.	
	A57	6,566,344	05/20/03	Gosselin, et al.	
	A58	6,566,365	05/20/03	Storer	
	A59	6,569,837	05/27/03	Gosselin, et al.	
	A60	6,573,248	06/03/03	Ramasamy, et al.	
	A61	6,596,700	07/22/03	Sommadossi, et al.	
	A62	6,599,887	07/29/03	Hostetler, et al.	
	A63	6,605,614	08/12/03	Bachand, et al.	
	A64	6,642,206	11/01/03	Ramasamy et al.	
	A65	6,660,721	12/09/03	Devos, et al.	
	A66	6,748,161	06/08/04	Ko, et al.	
	A67	6,752,981	06/22/04	Erion, et al.	
	A68	6,777,395	08/17/04	Bhat, et al.	
	A69	6,784,161	08/31/04	Ismaili, et al.	
	A70	6,784,166	08/31/04	Devos, et al.	
	A71	6,787,526	09/07/04	Bryant, et al.	
	A72	6,812,219	11/02/04	LaColla, et al.	
	A73	6,815,542	11/09/04	Hong, et al.	
	A74	6,831,069	12/14/04	Tam, et al.	
	A75	6,833,361	12/21/04	Hong, et al.	
	A76	6,846,810	01/25/05	Martin, et al.	
	A77	6,875,751	04/05/05	Imbach, et al.	
	A78	6,908,924	06/21/05	Watanabe, et al.	
	A79	6,911,424	06/28/05	Schinazi, et al.	
	A80	6,914,054	07/05/05	Sommadossi, et al.	
	A81	6,927,291	08/09/05	Jin, et al.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A82	6,946,115	09/20/05	Erion, et al.	
	A83	6,946,450	09/20/05	Gosselin, et al.	
	A84	6,949,522	09/27/05	Otto, et al.	
	A85	6,965,033	11/15/05	Jiang, et al.	
	A86	6,965,066	11/15/05	Jiang, et al.	
	A87	7,056,895	06/06/06	Ramasamy, et al.	
	A88	7,094,770	08/22/06	Watanabe, et al.	
	A89	7,101,861	09/05/06	Sommadossi, et al.	
	A90	7,105,493	09/12/06	Sommadossi, et al.	
	A91	7,105,499	09/12/06	Carroll, et al.	
	A92	7,125,855	10/24/06	Bhat, et al.	
	A93	7,144,868	12/05/06	Roberts, et al.	
	A94	7,148,206	12/12/06	Sommadossi, et al.	
	A95	7,151,089	12/19/06	Roberts, et al.	
	A96	7,157,434	01/02/07	Keicher, et al.	
	A97	7,157,441	01/02/07	Sommadossi, et al.	
	A98	7,163,929	01/16/07	Sommadossi, et al.	
	A99	7,169,766	01/30/07	Sommadossi, et al.	
	A100	7,202,224	04/10/07	Eldrup, et al.	
	A101	10/845,976	05/14/04	Storer, et al.	
	A102	11/005,443	12/06/04	Gosselin, et al.	
	A103	11/516,928	09/06/06	Sommadossi, et al.	
	A104	11/644304	12/22/06	Mayes, et al.	
	A105	2002/0019363	02/14/02	Ismaili, et al.	
	A106	2002/0035085	03/21/02	Somadossi, et al.	
	A107	2002/0052345	05/02/02	Erion, et al.	
	A108	2002/0055473	05/09/02	Ganguly, et al.	

LAI-3017173v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A109	2002/0055483	05/09/02	Watanable, et al.	
	A110	2002/0095033	07/18/02	Ramasamy et al.	
	A111	2002/0099072	07/25/02	Bachand, et al.	
	A112	2002/0127203	09/12/02	Albrecht	
	A113	2002/0156030	10/24/02	Ramasamy et al.	
	A114	2002/0173490	11/21/02	Jiang, et al.	
	A115	2002/0198171	12/26/02	Schinazi, et al.	
	A116	2003/0039630	02/27/03	Albrecht	
	A117	2003/0053986	03/20/03	Zahm	
	A118	2003/0055013	03/20/03	Brass	
	A119	2003/0083306	05/01/03	Imbach, et al.	
	A120	2003/0087873	05/08/03	Stuyver, et al.	
	A121	2003/0124512	07/03/03	Stuyver	
	A122	2003/0220290	11/27/03	Gosselin, et al.	
	A123	2003/0225028	12/04/03	Gosselin, et al.	
	A124	2003/0225029	12/04/03	Stuyver	
	A125	2003/0225037	12/04/03	Storer, et al.	
	A126	2003/0236216	12/25/03	Devos, et al.	
	A127	2004/0002476	01/01/04	Stuyver et al.	
	A128	2004/0002596	01/01/04	Hong, et al.	
	A129	2004/0006002	01/08/04	Sommadossi, et al.	
	A130	2004/0023921	02/05/04	Hong, et al.	
	A131	2004/0059104	03/25/04	Cook, et al.	
	A132	2004/0063622	04/01/04	Sommadossi, et al.	
	A133	2004/0063658	04/01/04	Roberts et al.	
	A134	2004/0067901	04/08/04	Bhat et al.	
	A135	2004/0072788	04/15/04	Bhat et al.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/715,729
	<b>Filing Date</b>	November 17, 2003
	<b>First Named Inventor</b>	Sommadossi, et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Humphrey, Louise W. Z.
	<b>Attorney Docket No.</b>	11874-064-999

### U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A136	2004/0077587	04/22/04	Sommadossi, et al.	
	A137	2004/0097461	05/20/04	Sommadossi, et al.	
	A138	2004/0097462	05/20/04	Sommadossi, et al.	
	A139	2004/0101535	05/27/04	Sommadossi, et al.	
	A140	2004/0102414	05/27/04	Sommadossi, et al.	
	A141	2004/0110717	06/10/04	Carroll, et al.	
	A142	2004/0110718	06/10/04	Devos, et al.	
	A143	2004/0121980	06/24/04	Martin, et al.	
	A144	2004/0147464	07/29/04	Roberts, et al.	
	A145	2004/0229839	11/18/04	Babu, et al.	
	A146	2004/0248844	12/09/04	Ismaili, et al.	
	A147	2004/0259934	12/23/04	Olsen, et al.	
	A148	2004/0266722	12/30/04	Devos, et al.	
	A149	2004/0266723	12/30/04	Otto, et al.	
	A150	2004/0266996	12/30/04	Microbiologica Quimica E Farmaceutica Ltd., Brazil	
	A151	2005/0009737	01/13/05	Clark, et al.	
	A152	2005/0020825	01/27/05	Storer, et al.	
	A153	2005/0031588	02/10/05	Sommadossi, et al.	
	A154	2005/0038240	02/17/05	Connolly, et al.	
	A155	2005/0090463	04/28/05	Roberts, et al.	
	A156	2005/0101550	05/12/05	Roberts, et al.	
	A157	2005/0107312	05/19/05	Keicher, et al.	
	A158	2005/0113330	05/26/05	Imbach, et al.	
	A159	2005/0119200	06/02/05	Roberts, et al.	
	A160	2005/0124532	06/09/05	Sommadossi, et al.	
	A161	2005/0137141	06/23/05	Hilfinger, et al.	

LAI-3017173v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A162	2005/0137161	06/23/05	Sommadossi, et al.	
	A163	2005/0215511	09/29/05	Roberts, et al.	
	A164	2006/0040890	03/23/06	Martin; et al.	
	A165	2006/0111311	05/25/06	Keicher, et al.	
	A166	2006/0166865	07/27/06	Sommadossi, et al.	
	A167	2006/0194835	08/31/06	Dugourd, et al.	
	A168	2006/0199783	09/01/06	Wang, et al.	
	A169	2006/0241064	10/26/06	Roberts, et al.	
	A170	2007/0015905	01/18/07	LaColla, et al.	
	A171	2007/0060503	03/15/07	Gosselin, et al.	
	A172	2007/0060504	03/15/07	Gosselin, et al.	
	A173	2007/0203334	08/30/07	Mayes, et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	CA 2252144	04/16/00	Miller, et al.		
	B02	DD 140254	02/20/80	Barwolff, et al.		
	B03	DE 102005012681	09/21/06	Weber, Lutz		
	B04	DE 1919307	01/14/71	Niedballa, et al.		
	B05	DE 2122991	11/16/72	Vorbruggen, et al.		
	B06	DE 2508312	09/02/76	Vorbruggen, et al.		
	B07	DE 4224737	02/03/94	Schott		
	B08	EP 0288847	04/16/88	Dobler, et al.		
	B09	EP 0352248	01/24/90	Medivir AB		
	B10	EP 0494119	01/03/92	Belleau, et al.		

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/715,729
	<b>Filing Date</b>	November 17, 2003
	<b>First Named Inventor</b>	Sommadossi, et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Humphrey, Louise W. Z.
	<b>Attorney Docket No.</b>	11874-064-999

### FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B11	EP 0526655	02/10/93	Japan Tobacco Inc.		
	B12	EP 0553358	08/04/93	Japan Tobacco Inc.		
	B13	EP 0587364	03/16/94	Britton, et al.		
	B14	EP 0742287	11/13/96	McGall, et al.		
	B15	EP 0747389	12/11/96	Taiho Pharmaceutical Co Ltd		
	B16	FR 1581628	09/19/69	Merck & Co. Inc.		
	B17	GB 1163102	09/04/69	Merck & Co. Inc.		
	B18	GB 1187824	05/02/66	Walton		
	B19	GB 1542442	03/21/79	Schering AG		
	B20	GB 924246	04/24/63	Wellcome Foundation, Ltd.		
	B21	GB 984877	03/03/65	Zellstoffabrik Waldhof		
	B22	JP 02091022	03/30/90	Univ. of Minnesota		
	B23	JP 06135988	05/17/94	Toagosei Chemical Ind., Ltd.		
	B24	JP 06211890	08/02/94	Yamasa Shoyu Co. Ltd.		
	B25	JP 06228186	08/16/94	Yamasa Shoyu Co., Ltd.		
	B26	JP 06293645	10/21/94	Jpn. Kokai Tokkyo Koho		
	B27	JP 09059292	03/04/97	Yamasa Shoyu Co. Ltd.		
	B28	JP 48048495	09/21/71	Kojin Co. Ltd.		
	B29	JP 61212592	09/20/86	Tokyo Tanabe Co. Ltd.		
	B30	JP 61263995	11/21/86	Takeda Chemical Ind., Ltd.		
	B31	JP 61263996	11/21/86	Boryung Pharmaceutical Co. Ltd.		
	B32	JP 63215694	09/08/88	Yamasa Shoyu Co. Ltd.		
	B33	JP 71021872	03/30/68	Sankyo Co., Ltd.		
	B34	WO 00/025799	05/11/00	Gosselin, et al.		
	B35	WO 01/032153	10/05/08	Biochem Pharma		
	B36	WO 01/049700	07/12/01	Biochem Pharma Inc., Can.		
	B37	WO 01/068663	09/20/01	Ribapharm Corp.		

LAI-3017173v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B38	WO 02/003997	01/17/02	Ribapharm, Inc. or ICN Pharmaceuticals?		
	B39	WO 03/039523	05/15/03	Wengel		
	B40	WO 03/051899	06/26/03	Ribapharm Inc.		
	B41	WO 03/061576	07/31/03	Ribapharm Inc.		
	B42	WO 03/062256	07/31/03	Ribapharm Inc.		
	B43	WO 03/062257	07/31/03	Ribapharm Inc.		
	B44	WO 03/063771	08/07/03	Pharmasset Inc.		
	B45	WO 03/068162	08/21/03	Pharmasset Inc.		
	B46	WO 03/068164	08/21/03	Pharmasset Inc.		
	B47	WO 03/068244	08/21/03	Merck & Co.; Isis Pharmaceuticals Inc.		
	B48	WO 03/072757	09/04/03	Biota Inc.		
	B49	WO 03/081899	06/26/03	Ribapharm Inc.		
	B50	WO 03/093290	11/13/03	Genelabs Technologies Inc.		
	B51	WO 03/099840	12/04/03	Eldrup, et al.		
	B52	WO 03/100017	12/04/03	Eldrup, et al.		
	B53	WO 03/105770	12/24/03	Eldrup		
	B54	WO 03/106577	12/24/03	Weikard, et al.		
	B55	WO 04/000858	12/31/03	Merck & Co. Isis Pharmaceuticals		
	B56	WO 04/007512	01/22/04	Merck & Co. Isis Pharmaceuticals		
	B57	WO 04/023921	03/25/04	Kim		
	B58	WO 04/028481	04/08/04	Genelabs Technologies, Inc.		
	B59	WO 04/041203	05/21/04	Xenoport, Inc.,		
	B60	WO 04/043977	05/27/04	Prakush, et al.		
	B61	WO 04/043978	05/27/04	Baker, et al.		
	B62	WO 04/044132	05/27/04	Baker, et al.		
	B63	WO 04/046159	06/03/04	F. Hoffmann-La Roche AG		

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B64	WO 04/046331	06/03/04	Idenix Cayman Limited		
	B65	WO 04/052899	06/24/04	Idenix Cayman Limited		
	B66	WO 04/058792	07/15/04	Idenix Cayman Limited		
	B67	WO 04/065398	08/05/04	Ribapharm, Inc.		
	B68	WO 04/072090	08/26/04	Merck & Co., Inc.		
	B69	WO 04/080466	09/23/04	Ribapharm, Inc.		
	B70	WO 04/084796	10/07/04	Pharmasset, Ltd.		
	B71	WO 04/096149	11/11/04	Idenix Cayman Limited		
	B72	WO 04/106356	12/09/04	Syddansk Universitet		
	B73	WO 05/003147	01/13/05	Pharmasset, Ltd.		
	B74	WO 05/012327	02/10/05	University College Cardiff Consultants Lmted		
	B75	WO 05/020884	03/10/05	CENT NAT RECH SCI.		
	B76	WO 05/020885	03/10/05	Isis Pharmaceuticals, Inc.		
	B77	WO 05/021568	03/10/05	Biota, Inc.		
	B78	WO 05/030258	04/07/05	Dihedron Corp.		
	B79	WO 05/042556	05/12/05	Genelabs Technologies, Inc.,		
	B80	WO 05/123087	12/29/05	Merck & Co., Inc.		
	B81	WO 06/002231	01/05/06	Biocryst Pharmaceuticals, Inc.		
	B82	WO 06/012078	02/02/06	Merck & Co., Inc.		
	B83	WO 06/012440	02/02/06	Wang, et al.		
	B84	WO 06/016930	02/16/06	Intermune, Inc.		
	B85	WO 06/037028	04/06/06	CENT NAT RECH SCI		
	B86	WO 06/037227	04/13/06	Migenix Inc., Can.		
	B87	WO 06/063717	06/22/06	Universitaet Karlsruhe		
	B88	WO 06/065335	06/22/06	Merck & Co. Inc.,		
	B89	WO 06/097323	09/21/06	Weber, Lutz		

LAI-3017173v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B90	WO 06/100087	09/28/06	Novartis A.G.		
	B91	WO 06/121820	11/16/06	Valeant Research & Development		
	B92	WO 06/130532	12/07/06	Novartis AG, Switz.		
	B93	WO 07/011777	01/25/07	Novartis A.-G., Switz.		
	B94	WO 07/025304	01/03/07	University of Oxford; Idenix Pharmaceuticals; et al.		
	B95	WO 92/015308	09/17/92	Wellcome Foundation, Ltd.		
	B96	WO 92/018517	10/29/92	Cheng, et al.		
	B97	WO 94/001117	01/20/94	Koszalka, et al.		
	B98	WO 98/016184	04/23/98	ICN Pharmaceuticals		
	B99	WO 99/023104	05/14/99	Klecker, et al.		
	B100	WO 99/052514	10/21/99	Eli Lilly and Co.		

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	AFDHAL, et al., Enhanced antiviral efficacy for valopicitabine plus PEG-interferon in hepatitis C patients with HCV genotype-1 infection. <i>Journal of Hepatology</i> 2005, Vol. 42, Supplement 2, p. 39-40.	
	C02	ALTMANN, et al., The Effects of 2'- and 3'-Alkyl Substituents on Oligonucleotide Hybridization and Stability, <i>Biorganic &amp; Medicinal Chemistry Letter</i> . 1994. 4. No. 16. 1969-74.	
	C03	AWANO, et al., "Nucleosides and Nucleotides, Part 144 Synthesis and Antiviral Activity of 5-Substituted (2's)-2'-Deoxy-2' -C-Methylcytidines and -Uridines," <i>Archiv Der Pharmazie</i> , VCH Verlagsgesellschaft MbH, Weinheim, DE, vol. 329, February 1, 1996, (1996-02-01), pp. 66-72.	
	C04	BEIGELMAN et al., "New synthesis of 2'-C-methylnucleosides starting from D-glucose and D-ribose" <i>Carbohydrate Res.</i> , 1987.166.,219-232	
	C05	BEIGELMAN et al., "Functionally complete analogs of nucleosides. The use of D-glucose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides. <i>Biorganicheskaya Khimiya</i> . 1986, Vol. 12(10), pp. 1359-65.	
	C06	BHOPALE, Girish Mahadeorao, et al., "Emerging drugs for chronic hepatitis C," <i>Hepatology Research</i> (2005), 32(3), 146-153.	
	C07	BIANCO A., et al. "Synthesis of a New Carbocyclic Nucleoside Analog", <i>Tetrahedron Letters</i> , 38(36):6433-6436, 1997	
	C08	BILLICH, et al., "Nucleoside Phosphotransferase from Malt Sprouts." <i>Biol. Chem. Hoppe-Seyler</i> , Vol. 367, pp. 267-278, April 1986.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C09	BIO, et al., "Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor." Journal of Organic Chemistry (2004), 69(19), 6257-6266.	
	C10	BLOCH A., et al., "The Role of the 5'-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase," J. Med. Chem., 10(5):908-12 (September 1967).	
	C11	BRYANT M.L., et al., "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," Antimicrobial Agents and Chemotherapy, 45(1):229-235 (January 2001).	
	C12	CAPPELACCI, et al. "Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists." Journal of Medicinal Chemistry (2005), 48(5), 1550-1562.	
	C13	CAPPELACCI, et al. "Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1' -C-methyl denosine analogues," J. Med. Chem., vol. 45, 2002, pp. 1196-1202.	
	C14	CARROLL, S.S., "Nucleoside analog inhibitors of hepatitis C virus replication," Infectious Disorders: Drug Targets (2006), 6(1), 17-29.	
	C15	CARROLL S.S., et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs," J. Biol. Chem., 278(14): 11979-11984 (2003).	
	C16	CAVELIER, F., et al., "Studies of Selective Boc Removal in the Presence of Silyl Ethers," Tetrahedron Letters, 37: 5131-5134 (1996).	
	C17	CHAND, Pooran; et al., "Synthesis of (2S,3S,4R,5R)-2-(4- amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." Collection Symposium Series (2005), 7(Chemistry of Nucleic Acid Components), 329-332.	
	C18	CHEN <i>et al.</i> , Heterocycles, vol. 28, no. 2, 1989, pp.593-601	
	C19	CHIACCHIO, et al., "Stereoselective synthesis of 2'-amino-2',3'dideoxynucleosides by nitron 1,3-dipolar cycloaddition: A new efficient entry toward d4T and its 2-methyl analogue," J. Org. Chem., vol. 64, 1999, pp. 28-36.	
	C20	CHIARAMONTE, et al., "Inhibition of CMP-Sialic Acid Transport into Golgi Vesicles by Nucleoside Monophates." Biochemistry 2001, 40, 14260-14267.	
	C21	CLARK, et al., Synthesis and antiviral activity...", Bioorganic & Medicinal Chemistry Letters, 16, 2006, 1712-1715.	
	C22	CLARK, et al., "Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication." Journal of Medicinal Chemistry (2005), 48(17), 5504-5508.	
	C23	COELMONT, Lotte, "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine," Antimicrobial Agents and Chemotherapy (2006), 50(10), 3444-3446.	
	C24	COOK, G.S., "Improving the treatment of hepatitis C infection in the UK," Expert Opinion on Pharmacotherapy, (2007) Vol. 8, No. 2, pp. 183-191.	
	C25	CORNBERG, M., et al., "Present and future therapy for hepatitis C virus," Expert review of Anti-Infective Therapy, (2006) Vol. 4, No. 5, pp. 781-793.	
	C26	CRETTON-SCOTT, E., et al., "Pharmacokinetics of B-L-2'-Deoxycytidine Prodrugs in Monkeys," Antiviral res., 50:A44 (2001).	
	C27	CZERNECKI, S., et al., "Synthesis of 2'-deoxy-2'-spirocyclopropyl cytidine as potential inhibitor of ribonucleotide diphosphate reductase," Can. J. Chem., vol. 71, 1993, pp. 413-416.	
	C28	DALPIAZ, et al., "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." European Journal of Pharmacology (2002), 448(2-3), 123-131	

LAI-3017173v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C29	DANIELS et al., "Tautomerism of Uracil and Thymine in Aqueous Solution: Spectroscopic Evidence", Proc. Nat. Acad. Sci. USA, Vol. 69, no. 9, pp. 2488-2491, 1972.	
	C30	DAVIS, G.L., "New Therapies: Oral Inhibitors and Immune Modulators," Clinics in Liver Disease, (2006) Vol. 10, No. 4, pp. 867-880.	
	C31	DAVISSON, V.J., et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," J. Org. Chem., 52(9):1794-1801 (1987).	
	C32	DING, et al., "Synthesis of 2'-b-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 725-727.	
	C33	DING, et al., "Synthesis of 9-(2-b-C-methyl-b-D-ribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 709-713	
	C34	DUTARTRE, H., et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," Antimicrobial Agents and Chemotherapy, (2006) Vol. 50, No. 12, pp. 4161-4169.	
	C35	ELDRUP et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication." Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(21), 5284-5297.	
	C36	ELDRUP, et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase.", Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(9), 2283-2295.	
	C37	FARQUHAR et al., "Biologically reversible phosphate-protective groups," J. Pharm. Sci., 1983, 72(3): 324	
	C38	FEAST, A.A.J., et al., "Studies on the D-Glucosaccharinic Acids," Acta Chemica Scandinavica 19(5):1127-1134 (1965).	
	C39	FOX, J. J., et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," J. Am. Chem. Soc., 81: 178-187 (January 5, 1959).	
	C40	FRANCESCO, et al. Antiviral Research 58 (2003) 1-16	
	C41	FRANCHETTI, et al., "Antitumor Activity of C-Methyl-b-D-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors." Journal of Medicinal Chemistry (2005), 48(15), 4983-4989.	
	C42	FUJIMORI, et al., "A Convenient and Stereoselective Synthesis of 2'-Deoxy-[beta]-L-nucleosides," Nucleosides & Nucleotides, 11(2-4), 341-349 (1992); only CAPLUS abstract supplied.	
	C43	FURUKAWA, Y., et al. "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," Chem. Pharm. Bull., 16(6):1076-1080 (June 1968).	
	C44	GALLO, et al., "2'-C-Methyluridine Phosphoramidite: A New Building Block for the Preparation of RNA Analogues Carrying the 2'-hydroxyl Group." Tetrahedron, 57 (2001), 5707-5713.	
	C45	GEROTTO, et al., Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Journal of Virology, September 1999, Vol. 73, No. 9, p. 7241-7247.	
	C46	GIRADET, et al., "Synthesis and Cytotoxicity of 4-Amino-5-oxopyrido[2,3-d]pyrimidine Nucleosides." Journal of Medicinal Chemistry (2000), 43(20), 3704-3713.	
	C47	GRETCH, D.R., "Use and interpretation of HCV diagnostic tests in the clinical setting." Clinics in Live Disease, November 1997, Vol. 1, No. 3, pp. 547-557.	
	C48	GROUILLER et al., "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent." J. Pharm.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Belg., 47(4), 381-3 (1992).	
	C49	GRUNNAGEL, et al., "Preparation of D-Tagatose." Justus Liebigs Annalen der Chemie (1969), 721: 234-5.	
	C50	HASSAN, et al., "Nucleosides and Nucleotides 151: Conversion of (Z)-2'-(Cyanomethylene)-2'-Deoxyuridines into their (E)-Isomers via Addition of Thiophenol to the Cyanomethylene Moiety Followed by Oxidative Syn-elimination Reactions." J. Org. Chem., vol. 61, 1996, pp. 6261-6267.	
	C51	HASSAN, et al., "Nucleosides and Nucleotides 156: Chelation-Controlled and Nonchelation-Controlled Diastereofacial Selective Thiophenol Addition Reactions at the 2'-Position of 2'-[(Alkoxy carbonyl)methyl]-2'-deoxyuridines: Conversion of (Z)-2'[(Alkoxy carbonyl)methyl]-2'-Deoxyuridines into their (E)-Isomers" J. Org. Chem., vol. 62, 1997, pp. 11-17.	
	C52	HATTORI, H. et al., "Nucleosides and Nucleotides 158" <i>Journal of Medicinal Chemistry, American Chemical Society</i> , Vol. 39, 1996, pp. 5005-5001	
	C53	HAYAKAWA, et al., "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2'- and 3'-positions." Chemical & Pharmaceutical Bulletin (1987), 35(6), 2605-8.	
	C54	HOARD, D.E., et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," J. Am Chem. Soc., 87(8):1785-1788 (April 20, 1965).	
	C55	HODGE, et al., "Amadori Rearrangement Products." Methods in Carbohydrate Chemistry (1963), 2: 99-107.	
	C56	HOLY, A., "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides for the Pyrimidine Series." Collect. Czech. Chem. Commun., 37(12): 4072-4087 (1972).	
	C57	HOSSAIN, et al., "Synthesis of 2'- and 3'-Spiro-isoxazolidine Derivatives of Thymidine & Their Conversions to 2',3'-dideoxy-2', 3'-didehydro-3'-C-substituted nucleosides by Radical Promoted Fragmentation," Tetrahedron Vol. 49, No. 44, pp. 10133-10156, (1993).	
	C58	HU, et al., "Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis, 2001, Vol. 8, p. 1-18.	
	C59	IGLESIAS, et al., "Complete and Regioselective Deacetylation of Peracetylated Uridines Using a Lipase." Biotechnology Letters 22: 361-365, 2000.	
	C60	IIMORI, et al., "2'-C-, 3'-C-, and 5'-C-Methylsangivamycins: conformational lock with the methyl group." Tetrahedron Letters (1991), 32(49), 7273-6.	
	C61	IIMORI, et al., "A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases." Nucleic Acids Symposium Series (1992), 27(Nineteenth Symposium on Nucleic Acids Chemistry, 1992), 169-70.	
	C62	IKEGASHIRA, K., et al., "Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors," Journal of Medicinal Chemistry, (30 Nov 2006) Vol. 449, No. 24, pp. 6950-6953.	
	C63	IMAI, K., et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." J. Org. Chem., 34(6): 1547-1550 (June 1969).	
	C64	KAKEFUDA, et al., "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: synthesis of 2',3'-dideoxy-2'-C-methyl- and -2'-C-ethynyl-b-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." Tetrahedron (1993), 49(38), 8513-28	

LAI-3017173v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C65	KAMAIKE, K., et al., "An efficient method for the synthesis of [4-15N]cytidine, 2'-deoxy[4-15N]cytidine, [6-15N]adenosine, and 2'-deoxy[6-15N]adenosine derivatives," Nucleosides and Nucleotides, 15(1-3): 749-769 (1996).	
	C66	KANEKO, M., et al., "A convenient synthesis of cytosine nucleosides," Chem. Pharm. Bull., 20:1050-1053 (1972).	
	C67	KEMPE, T., et al., "Selective 2'-Benzoylation at the Cis 2', 3'-diols of Protected Ribonucleosides. New Solid Phase Synthesis of RNA and DNA-RNA Mixtures," Nucleic Acids Res., 10(21):6695-6714 (November 11, 1982).	
	C68	KERR, S.G., et al., "N-(Dialkylamino)Methylene Derivatives of 2'-Deoxycytidine and Arabinocytidine: Physicochemical Studies for Potential Prodrug Applications," J. Pharm. Sci., 83(4): 582-586 (April 1994).	
	C69	KIM, et al., "A Novel Nucleoside Prodrug-Activating Enzyme: Substrate Specificity of Biphenyl Hydrolase-like Protein," Molecular Pharmaceutics (2004), 1(2), 117-127.	
	C70	KLUMPP, et al., "The Novel Nucleoside Analog R1479 (4'-Azidocytidine) is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture." The Journal of Biological Chemistry, Vol. 281, No. 7, pp. 3793-3799, February 17, 2006.	
	C71	KOHN, et al., "A new method for the synthesis of furanose derivatives of aldohexoses," J. Am. Chem. Soc., 1965, 87(23): 5475-80	
	C72	KOTRA, L., et al., "Structure-Activity Relationships of 2'-Deoxy-2',2'-difluoro-L-erythro-pentofuranosyl Nucleosides," J. Med. Chem. 1997, 40, 3635-3644.	
	C73	KUHN, R., et al., "Über eine molekulare Umlagerung von N-Glucosiden." Jahrg. 69, 1936, p. 1745-1754.	
	C74	LANDOWSKI, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," Journal of Pharmacology and Experimental Therapeutics (2006), 316(2), 572-580.	
	C75	LE POGAM, et al., "In Vitro Selected Con1 Subgenomic Replicons Resistant to 2'-C-Methyl-Cytidine or to R1479 Show Lack of Cross Resistance." Virology 351 (2006), 349-359.	
	C76	LE POGAM, et al., "Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus." Journal of Virology, Vol. 80, No. 12, June 2006, p. 6146-6154.	
	C77	LI, et al., "2' -C-Branched ribonucleosides. 2. Synthesis of 2' -C-beta-trifluoromethyl pyrimidine ribonucleosides," Org. Lett., vol. 3, 2001, pp. 1025-1028.	
	C78	LIN, T.S., et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," Tetrahedron Letters, 51(4): 1055-1068 (1995).	
	C79	LOPEZ APARICIO, F.J., et al., "Synthesis of Saccarinic Acid Derivatives," Carbohydrate Res., 129:99 (1984).	
	C80	LOPEZ-HERRERA, F.J., et al., "A New Synthesis of 2-C Methyl-D-Ribono-1, 4-Lactone and the C-(/C-13 Fragment of Methynolide," J. Carbohydrate Chemistry, 13(5): 767-775 (1994).	
	C81	MAGA, Giovanni, et al., Lack of stereospecificity of suid pseudorabies virus thymidine kinase," Biochem. J., 294(2): 381-385 (1993).	
	C82	MAHMOUDIAN, M., et al., "A Versatile Procedure for the Generation of Nucleoside 5'-Carboxylic Acids Using Nucleoside Oxidase," Tetrahedron, Elsevier Science Publishers Amsterdam, NL, vol. 54, no. 28, 8171-8182 July 9, 1998.	
	C83	MANSOUR, T.S., et al., "Editorial," Anti-Ineffective Agents in Medicinal Chemistry, (2007) Vol. 6, No. 1, pp. 1.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadosi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C84	MARKLAND W., et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," Antimicrobial Agents and Chemotherapy, April 2000, Vol. 44, No. 4, pp. 859-866.	
	C85	McFARLIN, et al., J. Am. Chem. Soc. 1958, 80, 5372-76.	
	C86	MILES, et al., "Circular Dichroism of Nucleoside Derivatives. IX. Vicinal Effects on the Circular Dichroism of Pyrimidine Nucleosides." J. Am. Chem. Soc. 92(13): 3872-3881 (1970).	
	C87	MOISEYEV, et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases." FEBS Letters (1997), 404(2,3), 169-172	
	C88	MOORE, et al., "Synthesis of Nucleotide Analogues That Potently and Selectively Inhibit Human DNA Primase." Biochemistry (2002), 41(47), 14066-14075.	
	C89	MURAI, et al., "A synthesis and an x-ray analysis of 2'-C-, 3'-C- and 5'-C-methylsanguivamycins," Heterocycles (1992), 33(1), 391-404.	
	C90	NISHIGUCHI, S., et al., "Methods to Detect Substitutions in the Interferon-Sensitivity-Determining Region of Hepatitis C virus 1b for Prediction of Response to Interferon Therapy," Hepatology. January 2001, Vol. 33, No. 1, pp. 241-247.	
	C91	NISHIMURA, T. et al. "Studies on Synthetic Nucleosides. Trimethylsilyl Derivatives of Pyrimidine and Purines," Chemical & Pharmaceutical Bulletin (1964), vol. 12, pp. 352-356.	
	C92	NOVAK, J.J.K. & Sorm, F., "Nucleic Acid Components and Their Analogues. CXX. 2-C-Methyl-D-Ribose and Its Derivatives," Collection Czechoslov. Chem. Commun., 34:857-866 (1969).	
	C93	NOVAK, J.J.K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C-Methyl-Erythro-D-Pentono-1, 4-Lactones," Collection Czechoslov. Chem. Commun., 39:869-882 (1974).	
	C94	OLSEN et al. (Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A76)	
	C95	PAGLIARO, L., et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. EPATOLOGIA: IERI, OGGI E (FORSE) DOMANI," Recenti Progressi in Medicina, (2006) Vol. 97, No. 12, pp. 741-750.	
	C96	PIERRA, C., et al., "Comparative Studies of Selected Potential Prodrugs of B-L-dC, A Potent and Selective Anti-HBV Agent," Antiviral Res., 50:A79 (2001), Abstract no. 138.	
	C97	PIERRA, C., et al., "NM 283, and efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," Nucleosides, Nucleotides and Nucleic Acids (2005), 24(5-7), 767-770.	
	C98	PIERRA, C., et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), and Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine," Journal of Medicinal Chemistry (2006), 49(22), 6614-6620.	
	C99	REIST, et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars." Journal of Organic Chemistry (1962), 27 3279-83.	
	C100	ROBINS, et al., "Purine Nucleosides. XXIX. The Synthesis of 2'-Deoxy-L-adenosine and 2'-Deoxy-L-guanosine and Their [alpha] Anomers," Journal of Organic Chemistry, 35(3), 636-639 (March 1970).	
	C101	RONG, et al., "The Synthesis and Conformation of 2'- and 3'-Hypermethylated Tricyclic Nucleosides and Their Use in the Synthesis of Novel 2'- or 3'-Isomeric 4(7)-Substituted Isoxazolidine-nucleosides," Tetrahedron Vol. 50, No. 16, pp. 4921-4936. (1994).	
	C102	ROQUE-AFONSO, AM, et al., "Performance of TRUGENE hepatitis C virus5' noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination," Journal of Viral Hepatitis. September 2002, Vol. 9, Issue 5, pp. 385-389.	

LAI-3017173v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C103	SAKTHIVEL, et al., "Electrophilic fluorination of 5- (cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3- deazaguanosine analogues." Synlett (2005), (10), 1586-1590.	
	C104	SAKTHIVEL, et al., "Direct SNAr amination of fluorinated imidazo[4,5- c]pyridine nucleosides: efficient syntheses of 3-fluoro-3deazaadenosine analogs." Tetrahedron Letters (2005), 46(22), 3883-3887.	
	C105	SALIDINO, R., et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," J. chem. Soc., Perkin Trans. I., 21: 3053-3054 (1994).	
	C106	SANDHU, et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." Drug Metabolism and Disposition (2004), 32(11), 1254-1259	
	C107	SATO, et al., "C-Nucleoside synthesis. 10. Synthesis of 2'-methylated pyrimidine C-nucleosides." Tetrahedron Letters (1980), 21(20), 1971-4.	
	C108	SATO, et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." Bulletin of the Chemical Society of Japan (1983), 56(9), 2680-99.	
	C109	SAVOCHKINA, et al., "Substrate properties of c - methyl nucleoside triphosphates in RNA syntheses catalyzed by e. coli RNA - polymerase" Molecular Biology, 1989, v. 23, no. 6.	
	C110	Scheibler, C., "Ueber das Saccharin und die Saccharinsäure," Chemische Berichte, 13:2212-2217 (1880). In German.	
	C111	Schiff, E.R., "Emerging strategies for pegylated interferon combination therapy," Nature Clinical Practice Gastroenterology and Hepatology, (2007) Vol. 4, No. SUPPL. 1, pp. S17-S21.	
	C112	Schmit, C., et al., "Synthesis of 2'-Deoxy-2' -Alpha-Monofluoromethyl and Trifluoromethylnucleosides," Synlett, Thieme Verlag, Stuttgart, DE, no. 4, 1994, pp. 241-242.	
	C113	Shalaby, et al., "Conformations and Structure Studies of Sugar Lactones in the Solid State. Part 11. The Molecular Structure of a-D-Glucosaccharino-Y-Lactone: 2-C-Mehtyl-D-Ribo-Pentono-1,4-lactone." Carbohydrate Research (1994), 264(2), 191-8.	
	C114	SHI, et al., Synthesis and in vitro Anti-HCV Activity of B-d- and 1-2'-Deoxy-2'-Fluororibonucleosides, Nucleosides, Nucleotides & Nucleic Acids 2005, Volume 23, Numbers 5-7, pp. 875-879.	
	C115	SHIM, Jae H., "Recent patents on nucleoside and nucleotide inhibitors for HCV," Recetn Patents on Anti-Infective Drug Discovery (2006), 1(3), 323-331.	
	C116	SINKO, et al., Carrier-Mediated Intestinal Absorption of Valacyclovir, the L-Valyl Ester Prodrug of Acyclovir. BIOPHARMACEUTICS & DRUG DISPOSITION 1998, Vol. 19, pp. 209-217.	
	C117	SINKULA et al., "Rationale for design of biologically reversible drug derivatives: prodrugs," J. Pharm. Sci., 1975,64: 181-210	
	C118	Smith, et al., "Synthesis of new 2'-b-C-methyl related triciribine analogues as anti-HCV agents." Valeant Pharmaceuticals International, Costa Mesa, CA, USA. Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3517-3520.	
	C119	Song, et al., Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevason, and hPEPT1-Medicated Transport," Molecular Pharmaceutics (2005), 2(2), 157-167.	
	C120	Sorbera, L.A., et al., "Valopicitabine: anti-hepatitis C virus drug RNA -directed RNA polymerase (NS5B) inhibitor," Drugs of the Future (2006), 31 (4), 320-324.	
	C121	Sowden, J., "The Saccharinic Acids," Adv. Carbohydrate Chem., 12:43-46 (1957).	
	C122	Spardari, et al., "L-Thmidine is Phosphorylated by Herpes Simplex Virus Type 1 Thymidine Kinase and Inhibits Viral Growth," Journal of Medicinal Chemistry, 35(22), 4214-4220 (1992).	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C123	Standring, D.N., et al., "Antiviral Beta-L-Nucleosides Specific for Hepatitis B Virus Infection," Antiviral Chem. & Chemother., 12 (Suppl. 1): 119-129 (2001).	
	C124	Stuyver, et al., "Ribonucleoside Analogue That Block Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture." Antimicrobial Agents and Chemotherapy, Vol 47, No. 1, Jan. 2003, p. 244-254.	
	C125	Sundberg, et al., Advanced Organic Chemistry, Part b, 1990, pages 232 and 236.	
	C126	Takenuki, et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2'-ketonucleosides." Chemical & Pharmaceutical Bulletin (1990), 38(11), 2947-52.	
	C127	Tang, X.-Q., et al., "2'-C-Branched Ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-B-Methylcytidine and Their Incorporation into Oligonucleotides," J. Org. Chem., 64(3): 747-754 (1999).	
	C128	The Merck Index, 12th edition, 1996, Page 275	
	C129	Tronchet, et al. "72. Synthese et desamination enzymatique des C-hydroxymethyl-3'-et C-methyl-3' -beta-D-xylofurannosyl-9-adenines," Helv. Chim. Acta, vol. 62, 1979, pp. 689-695.	
	C130	Tyrsted, G., et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxyadenosine and structurally related nucleoside analogs," Biochem. Biophys. Acta., 155(2): 619-622 (February 26, 1968).	
	C131	Velazquez, et al., "Synthesis of [1-[3',5'-bis-O-(tert-butylidimethylsilyl)-beta-D-arabino- and beta-D-ribofuransoyl] cytosine]-2'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T," Tetrahedron, vol. 50, 1994, pp. 11013-11022.	
	C132	Verri, A., et al., "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of B-L-deoxycytidine analogs as antineoplastic and antiviral agents," Molecular Pharmacology, 51(1): 132-138 (January 1997).	
	C133	Verri, a., et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues," Biochem. J., 328(1): 317-320 (November 15, 1997).	
	C134	Von Buren, et al., "Branched oligodeoxynucleotides: automated synthesis and triple helical hybridization studies." Tetrahedron (1995), 51(31), 8491-506.	
	C135	Von Janta-Lipinski, M., et al., "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified B-2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular SNA Polymerases a, B, y, d and E Nor HIV-1 Reverse Transcriptase," J. Medicinal Chemistry, 41(12): 2040-2046 (May 21, 1998).	
	C136	Wagner, D., et al., "Preparation and Synthetic Utility of Some Organotin Derivatives of Nucleosides," J. Org. Chem., 39(1):24-30 (1974).	
	C137	WALTON <i>et al.</i> , "Branched-chain sugar nucleosides. A new type of biologically active nucleoside," J. Am. Chem. Soc., 88(19): 4524-25 (1966)	
	C138	Whistler, R. L., and BeMiller, J.N., "[118] 'a'-D-Glucosaccharino-1,4-Lactone," Methods in Carbohydrate Chemistry, 2:484-485 (1963).	
	C139	Wohnsland, A., et al., "Viral determinants of resistance to treatment in patients with hepatitis C," Clinical Microbiology reviews, (2007) Vol. 20, No. 1, pp. 23-38.	
	C140	Wolf, et al., "New 2' -C-Branched-Chain Sugar Nucleoside Analogs With Potential Antiviral or Antitumor Activity," Synthesis, Georg Thieme Verlag, Stuttgart, DE, no. 8, August 1992 (1992-08), pp. 773-778.	
	C141	WU, et al., Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Current Drug Targets - Infectious Disorders 2003, Vol. 3, p. 207-219.	
	C142	ZEDECK <i>et al.</i> , "Inhibition of the steroid induced synthesis of $\Delta^5$ -3-ketosteroid isomerase in Pseudomonas	

LAI-3017173v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		testosteroni by a new purine deoxyribonucleoside analog: 6-chloro-8aza-9-cyclopentylpurinc," Mol. Phys., 3(4):386-95 (1967)	
	C143	Zemlicka, J., et al. "Aminoacyl Derivatives of Nucleosides, Nucleotides, and polynucleotides. VIII. The Preparation of 2'(3)-O-L-Phenylalanyluridine, -cytidine, - Adenonine, -inosine, -guanosine and 2'-Deoxy-3' O-L-Phenylalanyladenosine," Collection Czechoslov, Chem. Commun. 1969, Vol. 43, No. 13, 3755-3767.	
	C144	Zemlicka, J., et al., "Substrate Specificity of Ribosomal Peptidyltransferase. Peptidyltransferase. Effect of Modifications in the Heterocyclic, Carbohydrate and Amino Acid Moiety of 2'(3)-O-L-Phenyladenosine." Biochemistry. December 2, 1975, Vol. 14, No. 24, 5239-5249.	
	C145	ZHOU, et al., Pharmacokinetics and pharmacodynamics of valopicitabine. Journal of Hepatology 2005, Vol. 42 (Suppl. 2), p. 229.	
	C146	Zinchenko, et al., "2', 3' & .5' - uridine methyl derivatives in microbiological transelicozilation." Doklady Akad Nauk v.297(3), pp. 731-734 (1987).	
	C147	Zinchenko, et al., "Substrate specificity of uridine and purine nucleoside phosphorlases in whole cells of e. coli" Biopolymers & a cell, 1988, v. 4, No. 6.	
	C148	Zinchenko, et al., "Substrate Specificity of Uridine and Purine Nucleoside Phosphorylases of the Whole Cells of Escherichia Coli." Nucleic Acids Research, Symposium Series No. 18., 1987, pp. 137-140.	
	C149	Office Action dated October 1, 2003 from application number 09/863,816.	
	C150	Notice of Allowance dated June 23, 2004 from application number 09/863,816.	
	C151	Office Action dated August 27, 2003 from application number 09/864,078.	
	C152	Notice of Allowance dated February 19, 2004 from application number 09/864,078.	
	C153	Notice of Allowance dated May 17, 2005 from application number 10/602,135.	
	C154	Office Action dated April 5, 2005 from application number 10/602,135.	
	C155	Notice of Allowance dated March 9, 2006 from application number 10/602,136.	
	C156	Office Action dated July 28, 2006 from application number 10/602,142.	
	C157	Office Action dated September 20, 2007 from application number 10/602,142.	
	C158	Office Action dated December 10, 2008 from application number 10/602,142.	
	C159	Office Action dated November 15, 2005 from application number 10/602,142.	
	C160	Office Action dated March 29, 2007 from application number 10/602,142.	
	C161	Office Action dated February 26, 2008 from application number 10/602,142.	
	C162	Office Action dated May 30, 2006 from application number 10/602,691.	
	C163	Office Action dated August 22, 2007 from application number 10/602,691.	
	C164	Office Action dated October 7, 2008 from application number 10/602,691.	
	C165	Office Action dated December 29, 2006 from application number 10/602,691.	

LAI-3017173v1

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/715,729
	<b>Filing Date</b>	November 17, 2003
	<b>First Named Inventor</b>	Sommadossi, et al.
	<b>Art Unit</b>	1648
	<b>Examiner Name</b>	Humphrey, Louise W. Z.
	<b>Attorney Docket No.</b>	11874-064-999

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C166	Office Action dated November 7, 2005 from application number 10/602,691.	
	C167	Office Action dated February 26, 2008 from application number 10/602,691.	
	C168	Notice of Allowance dated December 28, 2005 from application number 10/602,692.	
	C169	Office Action dated April 5, 2005 from application number 10/602,692.	
	C170	Notice of Allowance dated December 27, 2005 from application number 10/602,693.	
	C171	Office Action dated April 6, 2005 from application number 10/602,693.	
	C172	Notice of Allowance dated December 27, 2005 from application number 10/602,694.	
	C173	Office Action dated April 6, 2005 from application number 10/602,694.	
	C174	Office Action dated September 10, 2004 from application number 10/602,976.	
	C175	Office Action dated May 19, 2005 from application number 10/602,976.	
	C176	Notice of Allowance dated October 13, 2005 from application number 10/602,976.	
	C177	Office Action dated 8/15/2006 from application number 10/608,907.	
	C178	Office Action dated 5/31/2007 from application number 10/608,907.	
	C179	Office Action dated 1/28/2008 from application number 10/608,907.	
	C180	Office Action dated November 26, 2008 from application number 10/608,907.	
	C181	Notice of Allowance dated April 7, 2009 from application number 10/608,907.	
	C182	Office Action dated August 2, 2006 from application number 10/609,298.	
	C183	Office Action dated July 10, 2008 from application number 10/609,298.	
	C184	Notice of Allowance dated April 7, 2009 from application number 10/609,298.	
	C185	Office Action dated October 5, 2005 from application number 11/005,440.	
	C186	Office Action dated December 5, 2006 from application number 11/005,440.	
	C187	Office Action dated June 13, 2007 from application number 11/005,440.	
	C188	Office Action dated October 16, 2007 from application number 11/005,440.	
	C189	Office Action dated August 21, 2006 from application number 11/005,441.	
	C190	Notice of Allowance dated June 22, 2007 from application number 11/005,441.	
	C191	Notice of Allowance dated January 8, 2008 from application number 11/005,441.	
	C192	Office Action dated August 7, 2006 from application number 11/005,442.	

LAI-3017173v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C193	Office Action dated May 16, 2007 from application number 11/005,442.	
	C194	Office Action dated November 28, 2007 from application number 11/005,442.	
	C195	Office Action dated October 5, 2005 from application number 11/005,443	
	C196	Office Action dated March 12, 2007 from application number 11/005,443	
	C197	Advisory Action dated August 8, 2007 from application number 11/005,443	
	C198	Office Action dated September 5, 2008 from application number 11/005,443	
	C199	Office Action dated October 12, 2005 from application number 11/005,444	
	C200	Office Action dated December 5, 2006 from application number 11/005,444	
	C201	Office Action dated June 13, 2007 from application number 11/005,444	
	C202	Office Action dated October 9, 2007 from application number 11/005,444	
	C203	Office Action dated October 6, 2008 from application number 11/005,444	
	C204	Office Action dated October 6, 2006 from application number 11/005,445	
	C205	Office Action dated February 26, 2008 from application number 11/005,445	
	C206	Office Action dated October 7, 2008 from application number 11/005,445	
	C207	Office Action dated July 17, 2008 from application number 11/005,445	
	C208	Notice of Allowance dated March 30, 2009 from application number 11/005,445.	
	C209	Office Action dated October 5, 2005 from application number 11/005,446	
	C210	Office Action dated December 5, 2006 from application number 11/005,446	
	C211	Office Action dated August 20, 2007 from application number 11/005,446	
	C212	Office Action dated March 17, 2008 from application number 11/005,446	
	C213	Notice of Allowance dated October 11, 2006 from application number 11/005,447	
	C214	Notice of Allowance dated February 12, 2007 from application number 11/005,447	
	C215	Notice of Allowance dated August 22, 2007 from application number 11/005,447	
	C216	Office Action dated October 12, 2005 from application number 11/005,466	
	C217	Office Action dated November 20, 2006 from application number 11/005,466	
	C218	Office Action dated June 13, 2007 from application number 11/005,466	
	C219	Office Action dated October 9, 2007 from application number 11/005,466	

LAI-3017173v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/715,729
<b>Filing Date</b>	November 17, 2003
<b>First Named Inventor</b>	Sommadossi, et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Humphrey, Louise W. Z.
<b>Attorney Docket No.</b>	11874-064-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C220	Office Action dated August 18, 2006 from application number 11/005,467	
	C221	Notice of Allowance dated August 22, 2007 from application number 11/005,467	
	C222	Office Action dated September 26, 2006 from application number 11/005,468	
	C223	Office Action dated June 14, 2007 from application number 11/005,468	
	C224	Office Action dated October 2, 2007 from application number 11/005,468	
	C225	Office Action dated October 5, 2006 from application number 11/005,469	
	C226	Office Action dated July 18, 2007 from application number 11/005,469	
	C227	Office Action dated March 24, 2008 from application number 11/005,469	
	C228	Notice of Allowance dated October 12, 2006 from application number 11/005,470	
	C229	Notice of Allowance dated March 7, 2007 from application number 11/005,470	
	C230	Notice of Allowance dated August 22, 2007 from application number 11/005,470	
	C231	Office Action dated July 18, 2007 from application number 11/005,471	
	C232	Office Action dated February 28, 2008 from application number 11/005,471	
	C233	Office Action dated October 12, 2005 from application number 11/005,472	
	C234	Office Action dated December 5, 2006 from application number 11/005,472	
	C235	Office Action dated June 13, 2007 from application number 11/005,472	
	C236	Office Action dated October 9, 2007 from application number 11/005,472	
	C237	Office Action dated November 25, 2005 from application number 11/005,473	
	C238	Notice of Allowance dated August 8, 2006 from application number 11/005,473	
	C239	Office Action dated October 2, 2009 from application number 11/516,928.	

LAI-3017173v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.